Clinical Trial Update: Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the feasibility and tolerability of neoadjuvant nivolumab immunotherapy in high-risk HPV-driven oropharyngeal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Cancer

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: UNICANCER | Conditions: Oropharynx Cancer | Phase 2 | Status: COMPLETED